Skip to main content

Content Validation of a Functional Co-Primary Measure for Clinical Trials Targeting Cognitive Impairment Associated With Schizophrenia (CIAS): An FDA-Funded Study

Publication ,  Conference
Horan, B; Depp, C; Hurst, S; Klein, H; Harvey, P; Keefe, R
Published in: NEUROPSYCHOPHARMACOLOGY
2022

Duke Scholars

Published In

NEUROPSYCHOPHARMACOLOGY

EISSN

1740-634X

ISSN

0893-133X

Publication Date

2022

Volume

47

Start / End Page

383 / 384

Related Subject Headings

  • Psychiatry
  • 5202 Biological psychology
  • 3209 Neurosciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Horan, B., Depp, C., Hurst, S., Klein, H., Harvey, P., & Keefe, R. (2022). Content Validation of a Functional Co-Primary Measure for Clinical Trials Targeting Cognitive Impairment Associated With Schizophrenia (CIAS): An FDA-Funded Study. In NEUROPSYCHOPHARMACOLOGY (Vol. 47, pp. 383–384).
Horan, Bill, Colin Depp, Samantha Hurst, Hans Klein, Philip Harvey, and Richard Keefe. “Content Validation of a Functional Co-Primary Measure for Clinical Trials Targeting Cognitive Impairment Associated With Schizophrenia (CIAS): An FDA-Funded Study.” In NEUROPSYCHOPHARMACOLOGY, 47:383–84, 2022.

Published In

NEUROPSYCHOPHARMACOLOGY

EISSN

1740-634X

ISSN

0893-133X

Publication Date

2022

Volume

47

Start / End Page

383 / 384

Related Subject Headings

  • Psychiatry
  • 5202 Biological psychology
  • 3209 Neurosciences
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences